Asian Tech Press (Mar. 24) -- BioNTech partner Fosun Pharma said it was still in talks to get approval for the launch of its mRNA COVID-19 vaccine in mainland China.

Chen Qiyu, executive director and co-CEO of Fosun International, revealed on Thursday at the company's online performance report that it is still in active communication for the approval of Fubitai to be marketed in mainland China.

Fubitai or BNT162b2, is a mRNA COVID-19 vaccine developed by Fosun Pharma in collaboration with German company BioNTech SE.

Chen also disclosed that by the end of February 2022, the vaccine had been totally administered to over 20 million doses in Hong Kong, Macau and Taiwan, with sales revenue of over $500 million.

The follow-up vaccination is also being accelerated in Hong Kong, Macau and Taiwan into 2022, Chen added.